|
**Overview**: **CKD Risk Map Profile****Introduction**: The CKD Risk Map Profile is a diagnostic tool designed to assess risk for chronic kidney disease using serum and urine samples. Associated with conditions like early-stage CKD and hypertension-related kidney damage, these disorders present with mild symptoms, hypertension, and severe complications if untreated, particularly in individuals at risk for kidney disease. Per the 2023 Biochemistry and Clinical Pathology guidelines, the test employs biochemistry and clinical pathology with spectrophotometry and microscopy technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for kidney risk assessment in clinical settings. This diagnostic falls under kidney risk assessment and targets individuals with risk factors for CKD, addressing the challenge of accurate parameter assessment to guide prevention. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its dual-sample approach ensures reliable detection.**Other Names**: CKD Risk Pfl.**FDA Status**: FDA approved, CLIA certified for biochemistry and clinical pathology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 1980s by nephrology labs, this test advanced CKD risk assessment.**Purpose**: The test screens for 11 parameters including creatinine to guide kidney risk assessment, assess renal function and protein excretion, and inform prevention and monitoring strategies.**Test Parameters**: 1. Creatinine, 2. Urea, 3. eGFR, 4. Urine Protein, 5. Urine Creatinine, 6. Urine Protein/Creatinine Ratio, 7. Urine Microalbumin, 8. Urine Albumin/Creatinine Ratio, 9. Sodium, 10. Potassium, 11. Glucose.**Pretest Condition**: Fasting 10-12 hours required; patients should report hypertension, mild symptoms, or recent kidney risk factors.**Specimen**: 3 mL serum in 1 SST, 10 mL urine in 1 sterile container, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours (Serum), 24 hours (Urine) with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days (Serum, Urine) at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months (Serum, Urine) at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on hypertension, mild symptoms, prior kidney reactions, or family history of renal disorders, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated CKD including renal failure, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using spectrophotometry and microscopy and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent hydration changes can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible CKD risk, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms or risk factors persist.**Specialist Consultation**: General practitioners or specialists in nephrology should be consulted for case management, prevention planning, and coordination with health programs.**Additional Supporting Tests**: Renal ultrasound or albuminuria follow-up for confirmation.**Test Limitations**: The test may produce false negatives in early disease stages or false positives in dietary variation, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Biochemistry and Clinical Pathology Guidelines 2023, Journal of Nephrology 2024, Chemistry 2025. |
